Journal article
Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis Reply
Authors
Lanctot KL; Paes B; Hui C; Chiu A; Tarride J-E
Journal
CURRENT MEDICAL RESEARCH AND OPINION, Vol. 25, No. 7, pp. 1632–1633
Publisher
LIBRAPHARM/INFORMA HEALTHCARE
Publication Date
July 1, 2009
ISSN
0300-7995